Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

AstraZeneca, Daiichi to jointly commercialize constipation drug Movantik in US AstraZeneca has entered into a co-commercialization agreement with the US unit of Daiichi Sankyo for distribution of its constipation drug, Movantik (naloxegol), a first-in-class once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA). Contract Research & Services > Contract Services > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

Actavis' DUR001-303 phase 3 study of single-dose Dalvance for ABSSSI meets end points
By PBR Staff Writer
Ireland based pharmaceutical firm Actavis has announced the top-line results for DUR001-303 which is a phase 3 study comparing a single 1500 mg dose of Dalvance with the same total dose given as two-doses one week apart.
News
Merck releases phase III data of grazoprevir/elbasvir to treat chronic hepatitis C virus
By PBR Staff Writer
Merck has released first presentations of data from C-EDGE phase III clinical trial of grazoprevir/elbasvir in patients with or without cirrhosis who are infected with chronic hepatitis C virus (HCV) genotypes 1, 4 or 6 (GT1, 4 or 6).
News

Contract Research

MedImmune enters into immuno-oncology clinical trial deal with Juno Therapeutics
By PBR Staff Writer
AstraZeneca's biologics research and development arm MedImmune has entered into collaboration with US-based biopharmaceutical firm Juno Therapeutics to conduct combination clinical trials in immuno-oncology.
News
Relmada begins pharmacokinetic trial for new oral formulations of buprenorphine
By PBR Staff Writer
US-based Relmada Therapeutics has started a proof-of-concept pharmacokinetic trial with its new formulations of oral, enteric-coated buprenorphine (BuTab, or REL-1028) being developed for both chronic pain and opioid dependence indications.
News

Contract Services

OWC, GC Group to develop new cannabinoid-based drugs
By PBR Staff Writer
One World Cannabis (OWC), a subsidiary of OWC Pharmaceutical Research, has entered into agreement with GC Group to develop new formulations and delivery methods targeting several medical indications.
News
Strategia begins Phase I/IIa trial of anti-cancer agent to treat advanced hematologic malignancies
By PBR Staff Writer
Strategia Therapeutics has initiated a Phase I/IIa clinical trial of anti-cancer agent E6201 to treat patients with advanced hematologic malignancies.
News